199 related articles for article (PubMed ID: 28113129)
1. Factors influencing the potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Hobson S; Lees P
Res Vet Sci; 2017 Apr; 111():93-98. PubMed ID: 28113129
[TBL] [Abstract][Full Text] [Related]
2. Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens.
Dorey L; Lees P
BMC Vet Res; 2017 Jun; 13(1):192. PubMed ID: 28645327
[TBL] [Abstract][Full Text] [Related]
3. Potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida: Comparison of growth media.
Dorey L; Hobson S; Lees P
Res Vet Sci; 2017 Apr; 111():43-48. PubMed ID: 27940285
[TBL] [Abstract][Full Text] [Related]
4. Activity of florfenicol for Actinobacillus pleuropneumoniae and Pasteurella multocida using standardised versus non-standardised methodology.
Dorey L; Hobson S; Lees P
Vet J; 2016 Dec; 218():65-70. PubMed ID: 27938711
[TBL] [Abstract][Full Text] [Related]
5. What is the true in vitro potency of oxytetracycline for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida?
Dorey L; Hobson S; Lees P
J Vet Pharmacol Ther; 2017 Oct; 40(5):517-529. PubMed ID: 28101885
[TBL] [Abstract][Full Text] [Related]
6. Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.
Dorey L; Pelligand L; Lees P
BMC Vet Res; 2017 Jul; 13(1):209. PubMed ID: 28666426
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial activity of tilmicosin against Pasteurella multocida and Actinobacillus pleuropneumoniae isolated from pneumonic lesions in swine.
Inamoto T; Kikuchi K; Iijima H; Kawashima Y; Nakai Y; Ogimoto K
J Vet Med Sci; 1994 Oct; 56(5):917-21. PubMed ID: 7865594
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of marbofloxacin for calf pneumonia pathogens.
Illambas J; Potter T; Cheng Z; Rycroft A; Fishwick J; Lees P
Res Vet Sci; 2013 Jun; 94(3):675-81. PubMed ID: 23375665
[TBL] [Abstract][Full Text] [Related]
9. In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs.
Blackall PJ; Asakawa T; Graydon RJ; White M; Adamson M; Wade LK; Lowe LB
Aust Vet J; 1995 Jan; 72(1):35-6. PubMed ID: 8787526
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Pelligand L; Cheng Z; Lees P
PLoS One; 2017; 12(5):e0177568. PubMed ID: 28552968
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida and Salmonella choleraesuis isolates from pigs.
Raemdonck DL; Tanner AC; Tolling ST; Michener SL
Vet Rec; 1994 Jan; 134(1):5-7. PubMed ID: 8128570
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial resistance genes in Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida isolated from Australian pigs.
Dayao D; Gibson JS; Blackall PJ; Turni C
Aust Vet J; 2016 Jul; 94(7):227-31. PubMed ID: 27349882
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Pelligand L; Cheng Z; Lees P
J Vet Pharmacol Ther; 2017 Oct; 40(5):505-516. PubMed ID: 28090673
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of doxycycline and oxytetracycline against porcine respiratory pathogens.
Bousquet E; Morvan H; Aitken I; Morgan JH
Vet Rec; 1997 Jul; 141(2):37-40. PubMed ID: 9253829
[TBL] [Abstract][Full Text] [Related]
15. Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella multocida and Actinobacillus pleuropneumoniae associated with porcine respiratory disease.
Shryock TR; Staples JM; DeRosa DC
J Vet Diagn Invest; 2002 Sep; 14(5):389-95. PubMed ID: 12296390
[TBL] [Abstract][Full Text] [Related]
16. Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine.
Moore GM; Basson RP; Tonkinson LV
Am J Vet Res; 1996 Feb; 57(2):224-8. PubMed ID: 8633813
[TBL] [Abstract][Full Text] [Related]
17. Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Blondeau JM; Fitch SD
PLoS One; 2019; 14(1):e0210154. PubMed ID: 30629633
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic integration and modelling of marbofloxacin in calves for Mannheimia haemolytica and Pasteurella multocida.
Potter T; Illambas J; Pelligand L; Rycroft A; Lees P
Vet J; 2013 Jan; 195(1):53-8. PubMed ID: 23084327
[TBL] [Abstract][Full Text] [Related]
19. Evaluation the kill rate and mutant selection window of danofloxacin against Actinobacillus pleuropneumoniae in a peristaltic pump model.
Wang H; Liao C; Ding K; Zhang L; Wang L
BMC Vet Res; 2024 Jun; 20(1):241. PubMed ID: 38831324
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model.
Qu Y; Qiu Z; Cao C; Lu Y; Sun M; Liang C; Zeng Z
BMC Vet Res; 2015 Dec; 11():294. PubMed ID: 26631082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]